MasterCraft Boat Holdings reported financial results for the first three months of its transition period, with net sales increasing 123.4% to $154.1 million. The growth was driven by the recent merger with Marine Products, which contributed $59.3 million in incremental sales, alongside a 37.4% increase in legacy business sales. The company is transitioning its fiscal year-end to December 31 following the merger completion.
Term
3 months ended Oct 4, 2026
“We delivered results above our expectations in the first quarter of the Transition Period, with total company net sales growing more than 120% year-over-year. Importantly, our legacy business net sales grew 37% and delivered Adjusted EBITDA growth of nearly 140%, reflecting the deliberate product, commercial, and operational actions we have taken across our business to drive premium mix, clean channels, and reduce costs.”
Brad Nelson, Chief Executive Officer
“The success of the next-generation X-Series is a clear example of the strength of our product and portfolio strategy and our ability to translate a deep understanding of our consumers into products that resonate in the market. Combined with our ongoing cost, productivity, and quality initiatives, those actions are driving stronger earnings and margin performance.”
Xilio Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting the dosing of the first patient in its Phase 1/2 trial for XTX501. The company ended the quarter with $45.1 million in cash and cash equivalents, which it expects will fund operations into the second quarter of 2027.
Term
Q3 2026
“In the third quarter, we initiated our Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific that we believe has the potential to become a foundational backbone immunotherapy regimen for solid tumors.”
René Russo, Pharm.D., president and chief executive officer of Xilio
Arbutus Biopharma reported a significant net income of $223.7 million for the nine months ended September 30, 2026, primarily driven by a $178.4 million settlement payment from Moderna and $67.3 million in dividend income. This represents a major turnaround from a net loss of $29.7 million in the prior year period, significantly strengthening the company's cash position to $264.2 million.
Exagen Inc. reported third quarter 2026 revenue of $18.4 million, a 7% increase year-over-year, driven by growth in test volume and average selling price. The company reduced its net loss to $6.3 million for the quarter and reiterated its full-year 2026 revenue guidance of $72 million to $75 million.
Term
Q3 2026
“Our third quarter extends what is fast becoming a record year for Exagen, and our ability to execute against our vision is increasingly evident in the results. The team grew the business again, with test volume and ASP both ahead of the same period last year.”
John Aballi, President and Chief Executive Officer of Exagen
Energy Focus, Inc. reported a significant increase in cash to $3.3 million as of September 30, 2026, compared to $1.1 million at year-end 2025, while inventories decreased from $2.9 million to $1.0 million. The company highlighted risks regarding its ability to continue as a going concern and its need for additional financing to maintain operations.
Ambiq Micro reported Q3 2026 net sales of $38.1 million, a 110% year-over-year increase driven by strong demand for edge AI solutions. The company achieved its sixth consecutive quarter of sequential revenue growth and expanded its active customer base by 50%. Management issued Q4 revenue guidance of $43.5 million to $44.5 million, signaling continued acceleration in demand.
Term
Q3 2026
“We delivered our sixth consecutive quarter of sequential net sales growth supported by healthy customer demand and strong supply chain partnerships that enabled us to secure capacity and meet growing customer needs. With demand for edge AI accelerating, we expect to deliver a meaningful step-up in net sales in the fourth quarter and another year of strong growth in 2027.”
Fumihide Esaka, CEO of Ambiq
“We believe we are still in the early stages of a significant, multi-year shift toward greater intelligence at the edge. With our differentiated technology, growing portfolio and expanding customer base, we believe Ambiq is well positioned to capture the significant opportunity ahead.”
Arbutus Biopharma reported Q3 2026 financial results, highlighting a strong cash position of $337.5 million following a $178.4 million settlement payment from Moderna. The company also announced expanded patent infringement litigation against Pfizer and BioNTech in Japan and Canada regarding its LNP technology.
Term
Q3 2026
“This has been a busy and productive quarter for the Arbutus team. I would like to congratulate our finance team, which successfully returned a substantial portion of Moderna’s first patent infringement payment to shareholders, and our R&D team, for achieving the lift of the 2023 U.S. FDA clinical hold on our oral PD-L1 inhibitor, AB-101, following a successful Phase 1 trial abroad.”
Kustom Entertainment reported its first quarter as a pure-play live entertainment and ticketing company following the divestiture of its legacy video business. Total revenue from continuing operations grew 57% to $2.7 million, and the company achieved net income of $2.3 million, significantly bolstered by a $5.0 million gain from discontinued operations.
Term
Q3 2026
“The third quarter was our first full quarter operating exclusively as a live entertainment and ticketing company, and the results show the strength of the business we have built. A 57% revenue expansion in continuing operations, driven by surging TicketSmarter transaction volume, demonstrates the scalability of our platform.”
Stanton E. Ross, Chief Executive Officer of Kustom Entertainment, Inc.
Vireo Growth reported Q3 2026 GAAP revenue of $253.7 million, a 177% increase year-over-year driven by recent M&A activity. The company achieved an annualized revenue run rate exceeding $1 billion and ended the quarter with $106.8 million in cash. Management highlighted the continued execution of its consolidation strategy and the pending merger with Planet 13.
Energy Focus reported Q3 2026 financial results with net sales of $4.8 million, a 481% increase year-over-year driven by the expansion of its Uninterruptible Power Supply (UPS) business in Taiwan. The company achieved profitability with net income of $0.5 million compared to a net loss in the prior year period, supported by higher commercial sales and a $184 thousand customs duty refund.
Cellectar Biosciences reported financial results for the third quarter of 2026, highlighting progress toward a planned accelerated approval filing for iopofosine I 131 in Waldenström macroglobulinemia (WM). The company remains on track to file its NDA with the FDA in the first half of 2027 and expects to dose the first patients in its Phase 3 confirmatory trial in Q1 2027.
Term
Q3 2026
“We remain focused on executing the clinical, regulatory and operational activities necessary to position iopofosine I 131 for potential registration and commercialization in Waldenström macroglobulinemia, and we believe our third quarter progress represents a significant step toward that goal.”
James Caruso, president and chief executive officer of Cellectar Biosciences
“To further maximize the long-term value of the program, we have initiated our Phase 1b dosimetry trial, which we believe offers an important opportunity to further characterize iopofosine I 131 across WM treatment settings, including first and second line.”
James Caruso, president and chief executive officer of Cellectar Biosciences
Autolus Therapeutics reported Q3 2026 financial results, highlighted by $41.2 million in AUCATZYL net product revenue, a 95% year-over-year increase. The company raised its full-year 2026 revenue guidance for AUCATZYL to meet or exceed $150 million, driven by increased demand and manufacturing efficiencies that improved gross margins to 57%.
“We delivered another strong quarter of AUCATZYL revenue, primarily driven by growth within existing authorized treatment centers as physicians gain positive experience with the therapy, and supported by real-world data reported through the ROCCA consortium.”
Dr. Christian Itin, Chief Executive Officer
“AUCATZYL’s performance in adult r/r B-ALL is a key near-term value driver. Longer term, we believe expanding obe-cel across all stages of ALL and into autoimmune indications offers meaningful opportunities for scalable growth, leveraging its favorable profile and Autolus’ proven manufacturing and commercial capabilities.”
Scholar Rock Holding Corp reported a net loss of $322.6 million for the nine months ended September 30, 2026, compared to $287.0 million in the prior year. The company recorded its first product revenue of $0.57 million in Q3 2026, while total liabilities increased significantly to $277.3 million due to new long-term debt financing.
908 Devices Inc. reported total revenue of $18.95 million for the third quarter of 2026, a 35% increase year-over-year. Despite the revenue growth, the company recorded a net loss of $4.58 million for the quarter, though this was a significant improvement from the $14.98 million net loss in the prior year period.
Passage Bio reported a net loss of $20.1 million for the nine months ended September 30, 2026, as it began winding down its gene therapy programs and entered into a merger agreement. Total assets decreased significantly from $62.3 million at year-end 2025 to $20.8 million, primarily due to the reduction in cash and the termination of lease assets.
CalciMedica reported third quarter 2026 financial results, ending the period with $13.8 million in cash which is expected to fund operations into the second half of 2027. The company highlighted clinical progress in its pulmonary hypertension and acute pancreatitis programs, with Phase 1b data for Auxora expected in mid-2027. Additionally, the company completed a 1-for-5 reverse stock split in August 2026 to regain Nasdaq compliance.
Term
3 years
“We continue to advance our pulmonary hypertension strategy, with data from the Auxora Phase 1b proof-of-concept trial in PH and the CM5480 IND submission both anticipated in mid-2027. Preclinical models suggest CRAC channel inhibitors may provide a differentiated approach in pulmonary hypertension by targeting multiple disease drivers, including right ventricular dysfunction, which is the principal cause of mortality and not directly targeted by existing therapies.”
Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica
Legend Biotech reported a significant turnaround for Q3 2026, achieving a net income of $51.7 million compared to a net loss of $39.6 million in the prior year, driven by higher CARVYKTI collaboration revenue and lower R&D and administrative expenses. Total revenue grew to $359.5 million, and the company achieved an operating income of $46.8 million.
Palladyne AI Corp. reported a significant revenue increase to $8.56 million for the third quarter of 2026, up from $0.86 million in the prior year, driven by its AI/ML technology commercialization efforts. Despite this growth, the company incurred a net loss from operations of $38.72 million for the first nine months of 2026 as it continues to invest heavily in research, development, and general administrative scaling.
Olema Pharmaceuticals reported a net loss of $189.9 million for the first nine months of 2026, compared to $116.4 million in the prior year, driven by a significant increase in research and development expenses. The company maintained a strong liquidity position with $413.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
Upstream Bio reported a net loss of $121.5 million for the nine months ended September 30, 2026, compared to $101.0 million in the prior year, driven primarily by increased research and development expenses for its lead candidate, verekitug. The company's cash, cash equivalents, and short-term investments totaled $207.4 million as of September 30, 2026, down from $341.5 million at the end of 2025.
Sionna Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis, specifically targeting the NBD1 domain. The company reports significant operating losses and anticipates needing substantial additional funding to advance its lead dual combination candidate, SION-451 + SION-2222, through clinical trials.
LENSAR reported third quarter 2026 financial results, highlighted by a 17% year-over-year increase in recurring revenue to $12.6 million despite a slight 1% decline in total revenue due to seasonal factors. The company expanded its ALLY System installed base to 225 units and reported a total laser installed base of 450 systems. While the company saw a net loss of $4.7 million, Adjusted EBITDA improved to $1.7 million compared to a loss in the prior year period.
Term
Q3 2026
“In-line with the expectations we shared in August, our third quarter results reflected the typical summer seasonality during which surgical scheduling and purchasing decisions contribute to a more measured pace of activity, leading to a sequential decline from a very strong second quarter.”
Nick Curtis, President and CEO of LENSAR
“Total revenue declined 1% year-over-year due to lower system sales against a robust number of sold systems in the prior year period, which was partially offset by growth in both procedure volume and recurring revenue.”
Cullinan Therapeutics, Inc. reported total assets of $322.6 million as of September 30, 2026, a decrease from $448.4 million at the end of 2025, primarily driven by a reduction in short-term and long-term investments. The company maintains a strong liquidity position with $289.6 million in cash, cash equivalents, and short-term investments to fund its clinical-stage product candidates. Total liabilities remained relatively stable at $41.3 million.
Hemab Therapeutics reported financial results for the third quarter of 2026 and provided a corporate update on its clinical pipeline. The company transitioned to a late-stage biotech by initiating the SOLARA Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia and dosing the first participant in a Phase 1 trial for HMB-003 in heavy menstrual bleeding.
Term
Q3 2026
“We are excited to have started our Phase 3 study in Glanzmann thrombasthenia, transitioning Hemab to a biotech company with clinical stage programs ranging from Phase 1 to Phase 3 across our portfolio.”
Benny Sørensen, MD, PhD, CEO of Hemab
“As our programs advance, we continue to expand our development efforts for larger, underserved markets across coagulation disorders, from the high-severity populations we started with to conditions like heavy menstrual bleeding that affect millions of women each year.”
Palladyne AI reported record Q3 2026 revenue of $8.6 million, representing 895% year-over-year growth driven by government contracts and its components business. The company raised the low end of its full-year 2026 revenue guidance to $25 million and reported a total backlog of $18.7 million. Management highlighted the successful field evaluation of SwarmOS by the U.S. Army and the commercial launch of the BRAIN FC-1 flight computer.
Term
Q3 2026
“We generated record revenues in the third quarter of $8.6 million, an increase of 895% year over year and up 48% sequentially. Compared to Q2, we saw a 26% increase in revenues associated with our components business, driven in part by our first delivery of our next generation BRAIN FC-1 flight computers. Our revenue from government contracts increased 135% quarter over quarter. Given our current trajectory, we are raising the low end of our full-year revenue guidance to $25 million, while reiterating the top end of $27 million.”
Cullinan Therapeutics reported third quarter 2026 financial results and provided a corporate update on its T cell engager portfolio. The company ended the quarter with $313.8 million in cash and investments, providing a projected cash runway into 2029. Key upcoming milestones include data readouts for CLN-978 in autoimmune indications and the completion of the zipalertinib NDA submission in November.
Term
Q3 2026
“Our progress this quarter underscores our ability to execute across a differentiated and rapidly advancing portfolio. In addition to the recent clinical success and regulatory progress of zipalertinib, we have advanced velinotamig into a global study in autoimmune cytopenias and initiated a potentially registrational Phase 2 study of CLN-049 in relapsed and refractory AML.”
Nadim Ahmed, President and CEO of Cullinan Therapeutics
“Looking ahead, we remain focused on strengthening our leadership position in the T cell engager space. This December, we will share an update for CLN-978 across our ongoing clinical trials in three autoimmune indications and will share updated data for CLN-049 at the ASH Annual Meeting. With multiple upcoming clinical catalysts and regulatory milestones, coupled with our strong balance sheet, we are well positioned to translate this momentum into meaningful progress for patients and long-term value for shareholders.”
Nadim Ahmed, President and CEO of Cullinan Therapeutics
Boundless Bio, Inc. has entered into a definitive merger agreement with Serapha Bio, Inc., which will result in significant ownership dilution for existing stockholders and a potential reverse stock split. The company remains a clinical-stage biopharmaceutical firm with no revenue, a limited operating history, and expectations of continued significant operating losses as it develops its extrachromosomal DNA (ecDNA) directed therapeutic candidates.
Sionna Therapeutics reported Q3 2026 financial results and announced plans to initiate the AscenSION CF Phase 2 proof-of-concept trial for its SION-451 and SION-2222 dual combination in Q1 2027. The company ended the quarter with $249.8 million in cash, which is expected to fund operations into the second half of 2029.
Term
Q3 2026
“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination. We believe the findings from the PreciSION CF post hoc analyses, together with the dual combination’s favorable Phase 1 results, support advancing the dual combination into the next phase of development. With our resources focused on developing this program and cash runway expected into the second half of 2029, we are well-positioned to execute our strategy to deliver new treatment options for people with CF.”
Mike Cloonan, President and Chief Executive Officer
Ovid Therapeutics reported a net loss of $52.8 million for the nine months ended September 30, 2026, compared to a $27.1 million loss in the prior year period. The increase in loss was primarily driven by a significant rise in research and development expenses, which grew from $19.0 million to $36.8 million year-over-year.
PepGen Inc. is a clinical-stage biotechnology company focused on developing PGN-EDODM1, its lead product candidate. The company remains pre-revenue, reporting significant accumulated losses and a continued need for substantial additional funding to support its research and development programs.